Terns Pharmaceuticals Surges 9.4% on $400M Capital Raise Amid Oncology Pipeline Momentum

Summary
• Terns Pharmaceuticals (TERN) surges 9.4% to $44.015, hitting a 52-week high of $45.17
• Announces $400M public offering to fund TERN-701 development and commercialization
• Intraday volume spikes to 4.47M shares, 5.9% of float
• Options volatility surges with 90%+ implied volatility on key December 19 contracts

The stock’s explosive move follows Terns’ announcement of a $400M capital raise, signaling aggressive funding for its flagship CML drug TERN-701. With a 9.4% intraday gain and a 52-week high reached, the market is reacting to the company’s strategic pivot toward commercialization readiness. The offering’s 30-day over-allotment option and lead underwriters’ involvement further amplify investor confidence in the pipeline’s potential.

Capital Raise Fuels Optimism in TERN-701 Pipeline
Terns’ 9.4% surge stems directly from its $400M public offering announcement, which includes a $60M over-allotment option. The proceeds will accelerate TERN-701’s clinical trials, manufacturing, and pre-commercialization activities for chronic myeloid leukemia (CML). With TERN-701 showing 64% major molecular response rates in early trials—surpassing Novartis’ Scemblix—the market is pricing in potential blockbuster status. The offering’s structure, led by Jefferies and Leerink, signals strong institutional backing, while the pre-funded warrants suggest a focus on broad investor participation. This capital influx directly addresses R&D bottlenecks and positions Terns to compete in the $2.5B CML market.

Options Playbook: Leveraging Volatility and Gamma in TERN’s Bull Run
• K-30D MA: $21.84 (below current price) • RSI: 78.88 (overbought) • MACD Histogram: +0.36 (bullish divergence) • Bollinger Upper Band: $35.53 (price at 123% of band)

TERN’s technicals scream short-term momentum: RSI near overbought territory, MACD divergence, and price trading 123% above its 30D MA. The 200D MA at $7.46 underscores a multi-year breakout. For options, focus on TERN20251219C44 and TERN20251219P44:

• TERN20251219C44 (Call, $44 strike, Dec 19 expiry):
- IV: 79.78% (high volatility)
- Delta: 0.53 (moderate directional bias)
- Theta: -0.189 (rapid time decay)
- Gamma: 0.065 (high sensitivity to price moves)
- Turnover: 17,394 (liquid)
- Leverage: 17.96% (aggressive payoff potential)
- Payoff at 5% upside: $46.21 → $2.21 profit per contract
- Why it stands out: High gamma and IV make it ideal for a continuation of TERN’s 9.4% move.

• TERN20251219P44 (Put, $44 strike, Dec 19 expiry):
- IV: 117.20% (extreme volatility)
- Delta: -0.457 (moderate bearish bias)
- Theta: -0.0717 (moderate time decay)
- Gamma: 0.0443 (moderate sensitivity)
- Turnover: 32,429 (high liquidity)
- Leverage: 12.43% (balanced risk/reward)
- Payoff at 5% upside: $46.21 → $2.21 profit per contract
- Why it stands out: High IV and turnover make it a hedge against a potential pullback after the 9.4% surge.

Action: Aggressive bulls should buy TERN20251219C44 into a breakout above $45.17 (52W high). Conservative traders may short TERN20251219P44 if the stock consolidates near $44.015.

Backtest Terns Stock Performance
Terns Pharmaceuticals (TERN) has experienced a complex performance trajectory since the 9% intraday surge in 2022. Here's a detailed analysis:1. Surge in 2022: The 9% intraday surge in 2022 was followed by a significant public offering in December of that year. TERN priced 10.35 million shares at $7.25 each, raising approximately $75 million. This offering was part of a broader strategy to fund the company's clinical-stage development pipeline and for working capital and general corporate purposes.2. Stock Performance Post-Offering: Following the offering, TERN's stock experienced a notable decline of 7.7% in the aftermarket session on December 21, 2022. This decline was likely due to market adjustments after the significant capital raise, as well as investor reactions to the dilution of shares.3. Subsequent Performance: In the months following the surge and the offering, TERN's stock has shown volatility. For instance, on August 12, 2022, TERN's stock rose by approximately 31% after pricing a $65 million stock/warrants offering. This offering included the sale of 12.25 million common shares and pre-funded warrants to certain investors, indicating ongoing efforts to fund the company's growth and development.4. Clinical Trial Updates: TERN's performance has also been influenced by the outcomes of its clinical trials. The company has highlighted positive data from its Phase 1 clinical trial of TERN-501, a thyroid hormone receptor beta agonist for the treatment of NASH. This trial showed time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy.5. Recent Performance: The most recent data available shows that TERN's stock has continued to fluctuate. For example, the company's stock price has been influenced by the ongoing Phase 2a DUET trial, which is evaluating TERN-501 alone and in combination with TERN-101 for the treatment of NASH. Top-line data from this trial are anticipated for the second half of 2023.6. Conclusion: Overall, TERN's performance since the 2022 surge has been marked by significant capital raises and fluctuations in stock price influenced by clinical trial outcomes and market reactions to capital raises. The company's ongoing clinical trials, particularly those involving TERN-501, are likely to play a crucial role in determining the stock's future trajectory.In conclusion, while TERN has shown potential with its clinical developments, the stock's performance has been affected by the capital raise and market adjustments. The ongoing clinical trials, especially those involving TERN-501, will be critical in shaping the company's future and its stock's performance.

Terns’ Capital Raise: A Catalyst for Long-Term Gains or Short-Term Volatility?
TERN’s 9.4% surge is a direct response to its $400M capital raise, which accelerates TERN-701’s path to commercialization. While the offering’s success hinges on regulatory and market conditions, the technicals and options data suggest continued short-term momentum. Watch for a breakout above $45.17 (52W high) to validate the bullish case. For context, sector leader Amgen (AMGN) fell 1.4%, underscoring TERN’s independent biotech rally. Investors should prioritize TERN20251219C44 for upside and TERN20251219P44 for downside protection. Key takeaway: If TERN sustains above $44.015, the 52W high becomes a critical inflection point for long-term positioning.